Protara completes enrollment in THRIVE-3 Phase 2b trial

October 15, 2026 8:00 AM

Protara Therapeutics, Inc. (Nasdaq: TARA) announced it has completed enrollment of the Phase 2b, open-label dose confirmation phase of its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found